Trials / Conditions / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

11 registered clinical trials studyying Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma.

Status	Trial	Sponsor	Phase
Completed	Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas NCT04774068	Walter Hanel	Phase 1
Terminated	Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633	Rutgers, The State University of New Jersey	EARLY_Phase 1
Completed	Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Ma NCT02342782	City of Hope Medical Center	Phase 1
Active Not Recruiting	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas NCT03598998	City of Hope Medical Center	Phase 1 / Phase 2
Completed	Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma NCT03534180	City of Hope Medical Center	Phase 2
Active Not Recruiting	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin NCT03278782	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractor NCT02978625	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymp NCT02520791	National Cancer Institute (NCI)	Phase 1
Completed	Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas NCT01897012	National Cancer Institute (NCI)	Phase 1
Completed	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533	National Cancer Institute (NCI)	Phase 1
Completed	Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell NCT01431209	University of Nebraska	Phase 2